Precision Diagnostics

• The FDA-cleared AXINON^® LDL-p Test System is a new tool physicians can use to measure lipoproteins for patients at risk for cardiovascular disease.

• AXINON^® lipoFIT^® is a cardiovascular risk assessment, available as a CE-labeled in vitro diagnostic product in the EU.  

• AXINON^® GFR(NMR) is a kidney function assay, available as a CE-labled in vitro diagnostic product in the EU. 
  Alex’ Story: Born with one kidney. What happens when it fails?

• AXINON^® HCC(NMR) is a liver cancer early detection test, currently in development. 

Cardiology

AXINON^® LDL-p Test System: Now FDA-cleared, provides more detailed information about cardiac function than the standard LDL-C (low-density lipoprotein or “bad cholesterol”) measurement.

AXINON^® lipoFIT^®: For cardiovascular risk assessment.

Available as a CE-labled in vitro diagnostic product in the EU 

Nephrology

AXINON^® GFR(NMR): New kidney function assay that combines two novel biomarkers, valine and myo-inositol, with creatinine and cystatin C using highly accurate nuclear magnetic resonance (NMR) spectroscopy.

Available as a CE-labled in vitro diagnostic product in the EU

Hepatology

AXINON^® HCC(NMR): Liver cancer early detection test.

In development